Table 3.

Multivariate analysis for overall and relapse free survival.

	Number	Events	aHR	95% CI	P value
	Overall survival
Treatment
Intensive chemotherapy	1199	928
Hypomethylating agents	1073	914	See R&P (Fig. 2C)a
Age - years
<75	1071	839	1
≥75	1201	1003	1.19	1.08–1.31	<0.001
ECOG performance status
0–1	1497	1189	1
2–4	587	507	1.56	1.41–1.74	<0.001
AML status
De novo	1420	1108	1
Secondary	680	597	1.21	1.09–1.34	<0.001
Cytogenetic risk
Favorable	56	41	1
Intermediate	1313	1023	0.91	0.67–1.25	0.570
Adverse	557	495	1.73	1.25–2.39	0.001
White blood cell count – giga per liter
≤30	1707	1396	1
>30	518	413	1.40	1.25–1.57	<0.001
NPM1 mutations
No	1383	1146	1
Yes	546	409	0.82	0.71–0.95	0.010

	Relapse-free survival
Treatment
Intensive chemotherapy	673	497
Hypomethylating agents	211	179	See R&P (Fig. 2D)a
ECOG performance status
0–1	661	500	1
2–4	159	131	1.24	1.02–1.52	0.031
AML status
De novo	617	461	1
Secondary	213	174	1.30	1.08–1.56	0.004
Cytogenetic risk
Favorable/ Intermediate	647	484	1
Adverse	148	126	1.58	1.28–1.95	<0.001
White blood cell count – giga per liter
≤30	644	500	1
>30	222	167	1.19	0.98–1.45	0.077
FLT3-ITD mutations
No	511	386	1
Yes	114	90	1.33	1.03–1.73	0.029
NPM1 mutations
No	382	303	1
Yes	230	160	0.71	0.57–0.87	0.001

aHR, adjusted hazard ratio; CI, confidence interval.

^aR&P: see Royston & Parmar.